Loading...

STLL

MSL

SATELLOS BIOSCIENCE INC

(MSLE)

2026 6-K

Interim Financial Report

15 May '26

Investor Conference

9 Apr '26

Financial Report

27 Mar '26

Clinical Data Update

10 Mar '26

Conference Announcement

24 Feb '26

Investor Conferences

19 Feb '26

KOL Event Announcement

18 Feb '26

Filing Submission

17 Feb '26

Pediatric Study Update

12 Feb '26

Biotech Summit Participation

10 Feb '26

Public Offering Completed

9 Feb '26

Filing Update

6 Feb '26

External Links:

SEC

On February 12, 2026, Satellos Bioscience Inc. reported that the first participant has been dosed in a Phase 2 pediatric study of SAT-3247 for Duchenne Muscular Dystrophy, marking a significant milestone for the company.

AI Assistant

SATELLOS BIOSCIENCE INC

2026

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.